Cyagen is an innovative Contract Research Organization (CRO) that was founded in 2006 to accelerate the research and development of new drugs using data, algorithms and animal models. The company is at the forefront of the industry in the field of gene editing animal models, with comprehensive services covering the entire process of model generation, from transgenic/gene targeting strategy design through model development, breeding, cryopreservation, and phenotype analysis.
Cyagen has continuously strengthened its advantages in data and models, combining many high-tech platforms such as target prediction and validation, viral vector development, evaluation model construction, and effectiveness evaluation. The company has also made significant achievements in the field of cell and gene therapy. With a team of expert researchers who harness cutting-edge technologies and technical expertise, Cyagen is dedicated to providing top-quality services to researchers in academia and industry worldwide.
Currently, Cyagen has more than 900 employees and a total scale of more than 40,000 square meters. The company has wholly-owned subsidiaries in Guangzhou, Suzhou, and Gu'an, China, and offices in Chengdu, Beijing, Shanghai, Wuhan, and Changsha. In addition, Cyagen has established subsidiaries worldwide, such as in Santa Clara, USA and Tokyo, Japan. The company has extensive cooperation with scientists, enterprises, and institutions in more than 100 countries and regions around the world, and its products and technologies have been directly applied to more than 6,300 academic papers including the three major journals of CNS (Cell, Nature, Science).
At Cyagen, we help our clients discover life. We are committed to creating a better future by partnering with global pharmaceutical developers to provide innovative solutions that accelerate the pace of scientific discovery. Our dedication to scientific excellence, combined with our cutting-edge technologies and exceptional customer service, make us a valuable asset to the scientific community.
Cyagen has continuously strengthened its advantages in data and models, combining many high-tech platforms such as target prediction and validation, viral vector development, evaluation model construction, and effectiveness evaluation. The company has also made significant achievements in the field of cell and gene therapy. With a team of expert researchers who harness cutting-edge technologies and technical expertise, Cyagen is dedicated to providing top-quality services to researchers in academia and industry worldwide.
Currently, Cyagen has more than 900 employees and a total scale of more than 40,000 square meters. The company has wholly-owned subsidiaries in Guangzhou, Suzhou, and Gu'an, China, and offices in Chengdu, Beijing, Shanghai, Wuhan, and Changsha. In addition, Cyagen has established subsidiaries worldwide, such as in Santa Clara, USA and Tokyo, Japan. The company has extensive cooperation with scientists, enterprises, and institutions in more than 100 countries and regions around the world, and its products and technologies have been directly applied to more than 6,300 academic papers including the three major journals of CNS (Cell, Nature, Science).
At Cyagen, we help our clients discover life. We are committed to creating a better future by partnering with global pharmaceutical developers to provide innovative solutions that accelerate the pace of scientific discovery. Our dedication to scientific excellence, combined with our cutting-edge technologies and exceptional customer service, make us a valuable asset to the scientific community.
Category Exhibitor Videos
07/25/2023
Video comments
😎 Cool video about Cyagen!!! Love the style!
✨ With years of experience and a team of highly trained experts, Cyagen can accelerate your research goals with all our cutting-edge biotechnological CRO services! From custom animal and cell line models, to iPSCs, cell and gene therapy, CAR-T/-NK, AI-AAV viral packaging, and evaluation services — we've got you covered.